Study #2024-0121
An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-112 in Human Leukocyte Antigen-C*08:02-positive adult subjects with unresectable, advanced, and/or metastatic solid tumors that are positive for the KRAS G12D mutation
MD Anderson Study Status
Enrolling
Treatment Agent
NT-112: Autologous, engineered T Cells targeting KRAS G12D
Description
Phase I Study of NT-112, an autologous T-cell therapy product genetically engineered to express an HLA-C\*08:02-restricted T cell receptor (TCR), targeting KRAS G12D mutant solid tumors.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer, Solid Tumor, Adult, KRAS G12D
Study phase:
Phase I
Physician name:
Maria Pia Morelli
Department:
Gastrointestinal Medical Oncology
For general questions about clinical trials:
1-833-992-0260
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.